Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study

TUCC physician, Lawrence Karsh, M.D., was a lead principal investigator in this Phase III clinical trial, published in The Lancet in February 2011.